X @Bloomberg
Bloomberg·2025-09-12 08:54
The next leg of a huge share-price rally for Belgium’s UCB — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug https://t.co/aQrLC6Ddkf ...
The next leg of a huge share-price rally for Belgium’s UCB — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug https://t.co/aQrLC6Ddkf ...